Pharma BD Deal Intelligence
Boehringer Ingelheim signed a binding agreement to acquire Swiss biotech NBE-Therapeutics for EUR 1.18B (~$1.4B); the deal closed March 4, 2021. It brought NBE's immune-stimulatory ADC (iADC) platform plus lead asset NBE-002 (zinitevatug), an anti-ROR1 ADC then in Phase 1 for TNBC and solid tumors, complementing Boehringer's antigen-discovery and T-cell-engager capabilities and entering the increasingly competitive ROR1 ADC race alongside Merck/VelosBio. Post-close, the program did not pan out: the NBE-002 Phase 1/2 trial (NCT04441099) was terminated for "End of Program" with a primary completion date of August 14, 2023, having enrolled only 12 of a planned ~100 patients. The acquisition's central clinical asset was thus discontinued, leaving the iADC platform as the residual value of the transaction.
Assessment window: 5yr post-close.